Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.67 |
| ▸ | MAOA | P21397 | 9/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15339484 | 0.92 | MAOA (0.65) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL1380514 | 0.89 | MAOA (0.65) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL1380521 | 0.89 | CALML3 (0.52) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL1380523 | 0.89 | CALML3 (0.52) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL12606250 | 0.86 | CALML3 (0.50) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL14839459 | 0.83 | CALML3 (0.73) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL1383450 | 0.82 | CALML3 (0.46) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL1382925 | 0.82 | MAOA (0.60) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL1382928 | 0.81 | MAOA (0.53) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL1382929 | 0.81 | MAOA (0.53) | CALML3MAOAMAOBCYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4739229-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| EP-1699784-A4 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2008-09-03 | — | — | EP | claimed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | claimed |
| EP-1699784-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | Dong-A Pharmaceutical Co., Ltd. (KR) | 2006-09-13 | — | — | EP | claimed |
| WO-2005058886-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG-A PHARM.CO.,LTD. (KR) | 2005-06-30 | — | — | WO | claimed |
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2021-04-29 | — | — | US | disclosed |
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2021-04-29 | — | — | US | disclosed |
| US-20200078345-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2020-03-12 | — | — | US | disclosed |
| US-20180344716-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2018-12-06 | — | — | US | disclosed |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-11-23 | — | — | US | disclosed |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-11-23 | — | — | US | disclosed |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-11-23 | — | — | US | disclosed |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2009-07-30 | — | — | US | disclosed |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2009-07-30 | — | — | US | disclosed |
| EP-1699784-A4 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2008-09-03 | — | — | EP | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
| EP-1699784-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | Dong-A Pharmaceutical Co., Ltd. (KR) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005058886-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG-A PHARM.CO.,LTD. (KR) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | CALML3 3337/4885MAOA 2505/4885MAOB 1905/4885 |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | ALPI, SI, TST | CALML3 1992/4885MAOA 4398/4885MAOB 4248/4885 |
| US-20200078345-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | CALML3 3337/4885MAOA 2505/4885MAOB 1905/4885 |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | ALPI, TPI1, SI | CALML3 2192/4885MAOA 3819/4885MAOB 3591/4885 |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | CALML3 3337/4885MAOA 2505/4885MAOB 1905/4885 |
| US-20180344716-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | CALML3 3337/4885MAOA 2505/4885MAOB 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.